Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original ResearchOmicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABooster